- Trials with a EudraCT protocol (237)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
237 result(s) found for: Percutaneous coronary intervention.
Displaying page 8 of 12.
EudraCT Number: 2014-004649-28 | Sponsor Protocol Number: CTO-201 | Start Date*: 2015-10-09 |
Sponsor Name:Matrizyme Pharma Corporation | ||
Full Title: A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Pla... | ||
Medical condition: The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularization | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005252-14 | Sponsor Protocol Number: KAI-9803-001 | Start Date*: 2005-04-21 | |||||||||||
Sponsor Name:KAI Pharmaceuticals Incorporated | |||||||||||||
Full Title: Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coro... | |||||||||||||
Medical condition: Acute myocardial infarction with ST elevation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003236-37 | Sponsor Protocol Number: 20160184 | Start Date*: 2018-11-02 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS) | ||||||||||||||||||
Medical condition: Dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002407-14 | Sponsor Protocol Number: 106915 | Start Date*: 2006-10-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research, European Medical Governance | |||||||||||||
Full Title: Eptifibatide Versus Abciximab in primary PCI for Acute ST elevation Myocardial Infarction (EVA-AMI) | |||||||||||||
Medical condition: Primary percutaneous coronary intervention (PCI) for ST-elevation Myocardial Infarction (STEMI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002547-25 | Sponsor Protocol Number: ARC1779-003 | Start Date*: 2007-12-19 | ||||||||||||||||
Sponsor Name:Archemix Corp. | ||||||||||||||||||
Full Title: A Phase 2 Study of an Aptameric von Willebrand Factor Antagonist, ARC1779, in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention | ||||||||||||||||||
Medical condition: ACS Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention (ST segemnt elevation MI and Non ST segemtn elevation MI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004877-38 | Sponsor Protocol Number: PREVENT-MINS | Start Date*: 2021-06-18 | |||||||||||
Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum | |||||||||||||
Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial | |||||||||||||
Medical condition: Myocardial Injury after Noncardiac Surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001495-11 | Sponsor Protocol Number: BAMI-01 | Start Date*: 2013-05-06 |
Sponsor Name:Queen Mary University London | ||
Full Title: The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction | ||
Medical condition: Myocardial Infarction with reduced Left Ventricular ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) CZ (Completed) FI (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001063-23 | Sponsor Protocol Number: 012357 | Start Date*: 2018-06-14 | |||||||||||
Sponsor Name:Queen Mary Innovation Centre, Queen Mary University of London | |||||||||||||
Full Title: PHASE II STUDY ASSESSING THE COMBINED USE OF AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELLS AND G-CSF WITH PERCUTANEOUS CIRCULATORY ASSISTANCE IN THE TREATMENT OF DILATED CARDIOMYOPATHY | |||||||||||||
Medical condition: Heart failure is caused by a cardiomyopathy, which is defined as a disorder of the heart muscle. Dilated cardiomyopathy (DCM) is characterised by enlargement of the ventricles and impaired systolic... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001348-24 | Sponsor Protocol Number: 3004 | Start Date*: 2012-09-10 |
Sponsor Name:Joslin Diabetes Center | ||
Full Title: A pilot study of allopurinol to prevent GFR loss in type 1 diabetes | ||
Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001883-31 | Sponsor Protocol Number: CARMRUSMIAMBULANCE20190823 | Start Date*: 2020-02-25 |
Sponsor Name:VU Univesity Medical Center (VUmc) | ||
Full Title: Microvascular Recovery using contrast Ultrasound in ST-elevation Myocardial Infarction in the ambulance (MRUSMI-Ambulance) | ||
Medical condition: ST elevation myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003050-41 | Sponsor Protocol Number: HJE-PHARMA-001 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Efficacy of GLP-1 agonists and restrictive vs. liberal FiO2 in patients undergoing coronary artery bypass grafting or aortic valve replacement – a 2-by-2 factorial designed, randomized clinical study | |||||||||||||
Medical condition: We investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replaceme... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005566-33 | Sponsor Protocol Number: CV185-398Wakili | Start Date*: 2016-06-14 | ||||||||||||||||
Sponsor Name:Klinikum der Universitaet Muenchen AoeR | ||||||||||||||||||
Full Title: APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF) | ||||||||||||||||||
Medical condition: Patients with acute coronary syndrome and atrial fibrillation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003903-23 | Sponsor Protocol Number: P150946J | Start Date*: 2018-03-02 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Assessment of Beta blocker interruption after uncomplicated mYocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization: The ABYSS Study | |||||||||||||
Medical condition: Myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000418-39 | Sponsor Protocol Number: EPREDICE2013 | Start Date*: 2015-01-20 | |||||||||||
Sponsor Name:EVIDEM CONSULTORES SL (EVIDEM) | |||||||||||||
Full Title: Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe | |||||||||||||
Medical condition: Non diabetic hyperglycaemia: Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) or both | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) AT (Ongoing) ES (Ongoing) LT (Prematurely Ended) GR (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002210-12 | Sponsor Protocol Number: COMPLETE-2013-05-01 | Start Date*: 2014-12-17 |
Sponsor Name:Population Health Research Institute | ||
Full Title: A randomized, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary intervention for ST-segm... | ||
Medical condition: Effectiveness study of complete versus culprit-only revascularization strategies to treat multi vessel disease after primary PCI for STEMI | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002699-42 | Sponsor Protocol Number: DANBLOCK | Start Date*: 2018-09-28 | |||||||||||
Sponsor Name:Bispebjerg Frederiksberg Hospital | |||||||||||||
Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) | |||||||||||||
Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000610-10 | Sponsor Protocol Number: RivAsA | Start Date*: 2020-01-27 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s... | ||||||||||||||||||
Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003590-24 | Sponsor Protocol Number: LPL104884 | Start Date*: 2006-03-01 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje... | ||
Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000860-25 | Sponsor Protocol Number: CSPP100E2337 | Start Date*: 2007-07-27 |
Sponsor Name:Novartis Farmacéutica, SA | ||
Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg... | ||
Medical condition: Diabetes tipo 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002747-16 | Sponsor Protocol Number: AR1108888 | Start Date*: 2008-10-27 | |||||||||||
Sponsor Name:GlaxoSmithKline R & D | |||||||||||||
Full Title: FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high... | |||||||||||||
Medical condition: Treatment of unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) ES (Completed) GB (Completed) FR (Completed) NL (Completed) IT (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
